Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Up 317.4% in November

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a large growth in short interest in November. As of November 30th, there was short interest totalling 175,300 shares, a growth of 317.4% from the November 15th total of 42,000 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily volume of 246,400 shares, the short-interest ratio is currently 0.7 days.

Wall Street Analysts Forecast Growth

Separately, Raymond James decreased their target price on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of XLO. Renaissance Technologies LLC lifted its stake in shares of Xilio Therapeutics by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after purchasing an additional 45,554 shares during the period. XTX Topco Ltd purchased a new stake in Xilio Therapeutics in the second quarter worth about $32,000. Finally, Geode Capital Management LLC grew its stake in shares of Xilio Therapeutics by 85.0% in the 3rd quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock worth $266,000 after buying an additional 155,337 shares during the last quarter. 54.29% of the stock is owned by institutional investors.

Xilio Therapeutics Trading Down 0.8 %

Shares of XLO stock traded down $0.01 during trading hours on Wednesday, hitting $1.06. 35,180 shares of the company’s stock were exchanged, compared to its average volume of 501,355. Xilio Therapeutics has a 12-month low of $0.49 and a 12-month high of $1.93. The business’s 50 day simple moving average is $0.98 and its 200-day simple moving average is $0.93. The company has a market capitalization of $46.43 million, a PE ratio of -0.62 and a beta of -0.29.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.